Ensuring Fair Access to Care for Inflammatory Bowel Disease: Obstacles and Strategies
Overview
The global burden of inflammatory bowel disease (IBD) is increasing rapidly, especially in low- and middle-income countries (LMICs), where access to quality care is limited. Disparities exist due to geographic, socioeconomic, racial, and structural factors, necessitating multifaceted strategies to improve equitable care worldwide.
Background
IBD, including Crohn’s disease and ulcerative colitis, has transitioned from a predominantly Western disease to a global health challenge, with cases rising sharply in newly industrialized regions. Managing IBD requires lifelong, multidisciplinary care, which is costly and complex. Access to care is uneven, with patients in LMICs and rural areas facing shortages of specialists and advanced diagnostics, while disadvantaged groups in high-income countries encounter financial and social barriers. Equity in care means addressing these diverse barriers to ensure comparable outcomes for all patients.
Data Highlights
Region/Group
Access Challenges
Outcomes
LMICs
Shortages of gastroenterologists, limited diagnostics, poor access to therapies
Delayed diagnosis, limited treatment options
Rural areas (USA, Canada)
Few specialists, long travel distances
Lower specialist visits, higher hospitalizations and emergency visits
Late diagnosis, less biologic use, underrepresentation in trials
Worse outcomes, reduced evidence applicability
Key Findings
IBD prevalence is rising globally, with significant increases in Asia, Africa, the Middle East, and Latin America.
Geographic disparities limit access to specialists and advanced diagnostics, especially in LMICs and rural areas.
Socioeconomic status strongly influences IBD outcomes, with lower SES linked to delayed treatment and higher hospitalizations.
Ethnic and racial minorities face later diagnoses, reduced access to biologics, and underrepresentation in clinical trials.
Structural issues such as shortages of IBD nurses, fragmented care, and lack of multidisciplinary teams exacerbate disparities.
Strategies to improve equity include policy reforms, expanding diagnostic and therapeutic capacity, telemedicine, patient involvement, and cultural competence training.
Clinical Implications
Clinicians should recognize the multifactorial barriers affecting IBD patients, particularly those in underserved regions or disadvantaged groups. Incorporating telemedicine and cost-effective diagnostics can help bridge gaps, while culturally competent care and patient engagement are essential to reduce stigma and diagnostic delays. Policy advocacy is needed to support equitable reimbursement and resource allocation.
Conclusion
Achieving equitable access to IBD care requires coordinated efforts across clinical, policy, and community domains to address geographic, socioeconomic, and structural barriers. Embedding equity into care models and leveraging innovations will be critical to improving outcomes globally.
References
Global Burden of Disease Study 2017 -- IBD Epidemiology
Health Equity and Access in IBD Care -- Review Article
